GUANGZHOU, China, Dec. 03, 2024 — Burning Rock Biotech Limited (NASDAQ: BNR), a precision oncology company using next-generation sequencing (NGS) technology, announced its annual general meeting (AGM) on December 31, 2024, at 10:00 a.m. (local time) at its Shanghai office (6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, Shanghai). Meeting details and proxy forms are available at https://ir.brbiotech.com.

The AGM will address:

1. Ratification of Ernst & Young Hua Ming LLP as the Company’s auditor for the fiscal year ending December 31, 2024, and authorization for the directors to determine auditor compensation;
2. Re-election of Yusheng Han and Gang Lu as directors;
3. Authorization for directors to take necessary actions to implement the above resolutions.

The board supports these proposals and recommends shareholder and ADS holder approval.

The record date for determining shareholders eligible for AGM notice is December 4, 2024 (New York time). Holders of Class A or Class B ordinary shares (US$0.0002 par value) as of the record date may attend. ADS holders must instruct Citibank, N.A., the depositary, to exercise voting rights for underlying Class A ordinary shares.

The board fully supports the proposed resolutions and recommends shareholder and ADS holder approval.

The Company’s amended Form 20-F annual report, including audited financials and auditor’s report for the year ended December 31, 2023, is filed with the SEC and accessible at https://ir.brbiotech.com and http://www.sec.gov.

About Burning Rock

Burning Rock Biotech Limited (NASDAQ: BNR) applies NGS technology to precision oncology, focusing on NGS-based therapy selection for late-stage cancer and clinical validation-stage cancer early detection.

Safe Harbor Statement

This release contains forward-looking statements, subject to risks and uncertainties under Section 21E of the Securities Exchange Act of 1934 and the U.S. Private Securities Litigation Reform Act of 1995. These statements, including beliefs and expectations, are based on current management expectations and may differ materially from actual results. All information is current as of today’s date, and Burning Rock disclaims any update obligation, except as required by law.

Contact: IR@brbiotech.com

“`